Renovaro Inc. (RENB)
Fuera de horario:
Renovaro Inc.
2080 Century Park East
Suite 906
Los Angeles, CA 90067
United States
305 918 1980
https://renovarobio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 12
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Hon. Mark R. Dybul M.D. | CEO, Director & Member of HBV Scientific Advisory Board | 764.58k | N/D | 1964 |
| Dr. Francois Binette M.Sc., Ph.D. | COO and Executive VP for Research & Development | 504.38k | N/D | 1964 |
| Dr. Serhat Gümrükcü | Co-Founder & Inventor | N/D | N/D | N/D |
| Mr. Simon Tarsh | Interim Chief Financial Officer | N/D | N/D | 1962 |
| Mr. Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations | N/D | N/D | N/D |
Descripción
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Renovaro Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
